O-RAN Alliance Releases First Software Code
Today, the O-RAN Alliance, working with the Linux Foundation, announced the O-RAN Software Community's first software code release, “Amber”.
The goal of the O-RAN Software Community is to advance opening the Radio Access Network (RAN) with a focus on the open interfaces, followed by implementations that leverage new capabilities enabled by the O-RAN specifications.
The Amber release includes initial contributions across 11 software projects. Key highlights include:
- The demonstration of the Operation and Maintenance O1 interface, including multi-vendor radio support.
- The initial release of the O-RAN unique Near Real-Time RAN Intelligent Controller. The Near-RT RIC aims at increasing network performance. It utilizes closed loop (~10ms) measurements to optimize load, energy consumption or other parameters across multiple radios. The O-RAN solution benefits from open access to local RAN data and leverages the O-RAN open architecture, including the E2 and O1 interfaces.
- 3 initial Near-RT RIC microservices (X-APPs) on network admission control, network KPI monitoring and KPI measurement.
- An initial RAN protocol stack from 4G LTE with extendable framework towards 5G standalone mode that leverages the multi-vendor O-RAN architecture with the open fronthaul interface and the F1 interface.
The Amber Release is available at the O-RAN Software Community wiki pages.
The O-RAN Software Community plans to continue rapid development of O-RAN compliant software, following the Linux Foundation 6 months release cycle.
“The first release of the O-RAN Software Community exemplifies the progress we've made as an industry, and AT&T is proud to be a member and active contributor of this effort," said Andre Fuetsch, Chairman of the O-RAN Alliance, Executive Vice President and Chief Technology Officer of AT&T. “Together, we’re driving forward open networking, software and virtualization in global wireless networks, which is critical as we shift to a 5G world.”
"We are really pleased to deliver the first release of the O-RAN Software Community with key elements in both repositories in such a short period of time," said Chih-Lin I, Co-chair of O-RAN Technical Steering Committee (TSC), Chief Scientist of China Mobile. "The Amber Release provides a good framework for the non-realtime RIC and the near-realtime RIC under Apache 2.0, as well as the O-CU and the O-DU under the FRAND-based O-RAN Software License. It demonstrates the value of close alignment between the specification work and the corresponding open source software development.”
“The TOC is proud of all the contributors who have worked hard to bring together the first release of software for an open and intelligent RAN in such a short time,” said John Murray, co-chair of the O-RAN Software Community Technical Oversight Committee and AVP advanced technologies, AT&T. “It is an exciting and evolving domain that is at the front of technology changing our world. The first release is the start of the project and we expect the contributions and functionality to continue as we grow the community of contributors and deliver additional releases in the future.”
“At Nokia we are strong proponents of O-RAN’s core principles of intelligence and openness and believe it will motivate collaboration and drive innovative new services in the industry,” said Michael Clever, Head of Cloud RAN Solutions at Nokia. “We are pleased to be contributing to the Near-RT RIC software in the O-RAN Amber Release. This and future contributions will help prove out the Near-RT RIC and pave the way for wider adoption.”
“Radisys is a champion of O-RAN Alliance and our open strategy has been a guiding beacon for us to help foster the open RAN ecosystem,” said Neeraj Patel, SVP and GM, MobilityEngine Business Unit, Radisys. “We have been working with the O-RAN Alliance and Linux Foundation to bring an open O-DU and O-CU protocol stack as part of the Amber Release. Radisys will continue to play an active role both as an enabler and integrator to fast track the operationalization and commercialization of a multi-vendor ecosystem for 5G RAN.”
“We are pleased to see the O-RAN Software Community issue its first software release, especially in such a short time since forming the project,” said Arpit Joshipura, general manager, Networking, Edge and IoT, the Linux Foundation. “The speed in which this collaboration came together represents a strong commitment across the open source networking ecosystem towards the harmonization of both open source and open standards, as well as cross-stack integration.”
About O-RAN Alliance and the O-RAN Software Community
The O-RAN Alliance is a world-wide, carrier-led effort with more than 130 member operators, vendors, and research & academic institutions operating in the Radio Access Network industry. Its mission is to drive new levels of openness in the radio access network of next generation wireless systems. Future RANs will be built on a foundation of virtualized network elements, white-box hardware and standardized interoperable interfaces that fully embrace O-RAN’s core principles of intelligence and openness.
For more information please visit www.o-ran.org.
The O-RAN Software Community was jointly created by the O-RAN Alliance and the Linux Foundation in April 2019. Its mission is to provide a software solution to support the implementation of an open and intelligent Radio Access Network (RAN), compliant with the O-RAN Alliance specifications.
For more information please visit www.o-ran-sc.org.
About the Linux Foundation
Founded in 2000, the Linux Foundation is supported by more than 1,000 members and is the world's leading home for collaboration on open source software, open standards, open data, and open hardware. Linux Foundation's projects are critical to the world's infrastructure including Linux, Kubernetes, Node.js, and more. The Linux Foundation's methodology focuses on leveraging best practices and addressing the needs of contributors, users and solution providers to create sustainable models for open collaboration. For more information please visit us at www.linuxfoundation.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191203005530/en/
Contact information
Zbynek Dalecky
O-RAN Alliance e.V.
pr@o-ran.org
+420 603 400 524
Jill Lovato
The Linux Foundation
jlovato@linuxfoundation.org
+1 503 703 8268
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations for treatment-resistant depression (TRD) from 10:00-11:30 am ET on January 7th. “PTSD is one of the most challenging mental health conditions, with approximately 13 million adults in the U.S. living with persistent symptoms and limited treatment options,” said Dr. Guy Goodwin, Chief Medical Officer at Compass Pathways. “We are pleased to advance our clinical development - the unmet need is profound, and it demands bold innovation. We believe COMP360 has the potential to tra
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom